ProCE Banner Activity

Video Roundtable: Immunotherapy in Endometrial Cancer

In this engaging interactive video, watch 3 global experts discuss emerging data, evolving treatment standards, and gaps in the optimal care of patients with endometrial cancer.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: January 04, 2021

Expiration: January 03, 2022

No longer available for credit.

Share

Faculty

Ana Oaknin

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Supporters

Supported by an educational grant from

GlaxoSmithKline

Target Audience

This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with endometrial cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate current and emerging clinical trial data regarding new immunotherapy treatment options for patients with endometrial cancer
  • Identify current and emerging recommendations for molecular profiling in endometrial cancer and implications for prognosis and treatment decisions
  • Manage the unique adverse events associated with the emerging, novel treatment options for endometrial cancer
  • Describe the role of immune checkpoint inhibitors as single agents or in combination to treat endometrial cancer classified as microsatellite stable
  • Evaluate current and emerging clinical trial data regarding new immunotherapy treatment options for patients with endometrial cancer

Program Director Disclosure

Program Director

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Ana Oaknin, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, Clovis Oncology, Genmab, Immungen, PharmMar, Roche, and Tesaro.

Faculty Disclosure

Primary Author

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no real or apparent conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Goal


The goal of this activity is to improve the knowledge of global learners to apply practice-changing clinical data and expert recommendations to optimize the care of patients with endometrial cancer.